Pfizer CEO Albert Bourla goes one-on-one with Jim Cramer
Pfizer Chairman and CEO Albert Bourla joins 'Mad Money' host Jim Cramer to talk quarterly results, what's in the pipeline, ...
Pfizer CEO defends turnaround strategy as activist pressures management
By Michael Erman and Bhanvi Satija (Reuters) -Pfizer CEO Albert Bourla, under pressure from activist hedge fund Starboard ...
Pfizer rides Paxlovid sales growth to better-than-expected third quarter
A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the ...
Pfizer’s Hold Rating Maintained Amid Unsustainable Surprises and Limited Growth Prospects
Analyst Chris Schott from J.P. Morgan maintained a Hold rating on Pfizer (PFE – Research Report) and keeping the price target at $30.00.
Pfizer CEO: The activist investors are 'too late'
Pfizer had a "constructive" meeting with activist investor Starboard Value last week and spoke publicly about it for the ...
Pfizer Q3 Revenue, EPS Exceed Estimates
Pfizer reported an adjusted EPS of $1.06, exceeding estimates by over 72%. Revenue reached $17.7 billion, marking a 32% year ...
Heard on the Street: Pfizer Stock Is a Bargain for Patient Investors
After losing nearly half of its market value since its Covid-19 peak, Pfizer’s stock represents a bargain for patient ...
Pfizer’s earnings crush estimates as company raises guidance
Pfizer Inc.’s stock was unable to hold its early gains Tuesday and fell 2.4% after the company blew past estimates for the ...
Pfizer’s Balanced Outlook: Hold Rating Amid Strong Q3 Results and Future Challenges
Morgan Stanley analyst Terence Flynn maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $30.00.
Will Pfizer Beat Earnings In Q3?
We think Pfizer’s top line will see growth in the low teens, driven by market share gains for Vyndaqel and Abrysvo.
Pfizer’s Strong Quarter Bolsters CEO’s Comeback Efforts
It also raised its guidance on adjusted annual earnings per share to a range of $2.75 to $2.95 per share, up from between $2.45 to $2.65 per share.The encouraging third quarter comes as Pfizer faces ...